According to foreign media reports, the American company Modena announced on the 26th that it has begun a clinical trial to study the safety and efficacy of vaccine enhancement injections specifically for the new crown variant virus Omiljung strain. The U.S. fluorine Pharmaceutical Company and the German biotech company have previously announced that they have begun trials of a new version of the vaccine against the Omiljun strain. Albert Brah, CEO of Pfizer, believes that the Omilton strain has led to a large number of cases of "breakthrough infection" in vaccinated populations in many places, and a vaccine specifically targeting the Omiljun strain will reduce the risk of "breakthrough infection". (China News Service)
